Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. The company currently markets FDA-approved products: Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN); Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain. See Important Safety Information for Gralise, Cambia, and Zipsor.
In December 2017, Depomed announced the signing of a definitive Commercialization Agreement with Collegium Pharmaceutical under which Collegium will commercialize the NUCYNTA® pain franchise and Depomed will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.
Depomed has recently acquired and is developing cebranopadol, a novel, Phase III ready, first-in-class analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.
In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA® ER and Gralise.
The company’s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options patient populations that may be underserved by existing therapies.